Search Results - "Abbott, Joshua M"

High-Content Drug Discovery Targeting Molecular Bladder Cancer Subtypes by Rinaldetti, Sébastien, Zhou, Qiong, Abbott, Joshua M., de Jong, Florus C., Esquer, Hector, Costello, James C., Theodorescu, Dan, LaBarbera, Daniel V.

“…Molecular subtypes of muscle-invasive bladder cancer (MIBC) display differential survival and drug sensitivities in clinical trials. To date, they have not…”
Get full text

Design, Synthesis, and Biological Evaluation of the First Inhibitors of Oncogenic CHD1L by Prigaro, Brett J, Esquer, Hector, Zhou, Qiong, Pike, Laura A, Awolade, Paul, Lai, Xin-He, Abraham, Adedoyin D, Abbott, Joshua M, Matter, Brock, Kompella, Uday B, Messersmith, Wells A, Gustafson, Daniel L, LaBarbera, Daniel V

“…Chromodomain helicase DNA-binding protein 1 like (CHD1L) is an oncogene implicated in tumor progression, multidrug resistance, and metastasis in many types of…”
Get full text

First-in-Class Inhibitors of Oncogenic CHD1L with Preclinical Activity against Colorectal Cancer by Abbott, Joshua M, Zhou, Qiong, Esquer, Hector, Pike, Laura, Broneske, Travis P, Rinaldetti, Sébastien, Abraham, Adedoyin D, Ramirez, Dominique A, Lunghofer, Paul J, Pitts, Todd M, Regan, Daniel P, Tan, Aik Choon, Gustafson, Daniel L, Messersmith, Wells A, LaBarbera, Daniel V

“…Since the discovery of CHD1L in 2008, it has emerged as an oncogene implicated in the pathology and poor prognosis of a variety of cancers, including…”
Get full text

Drug Design Targeting T‑Cell Factor-Driven Epithelial–Mesenchymal Transition as a Therapeutic Strategy for Colorectal Cancer by Abraham, Adedoyin D, Esquer, Hector, Zhou, Qiong, Tomlinson, Nicholas, Hamill, Brayden D, Abbott, Joshua M, Li, Linfeng, Pike, Laura A, Rinaldetti, Sébastien, Ramirez, Dominique A, Lunghofer, Paul J, Gomez, Jose D, Schaack, Jerome, Nemkov, Travis, D’Alessandro, Angelo, Hansen, Kirk C, Gustafson, Daniel L, Messersmith, Wells A, LaBarbera, Daniel V

“…Metastasis is the cause of 90% of mortality in cancer patients. For metastatic colorectal cancer (mCRC), the standard-of-care drug therapies only palliate the…”
Get full text